2026-525342-29-00CompletedPhase 1
A Study to Establish the Bioequivalence of Free Acid Tafamidis 61 mg Capsule and Tablet, and Evaluate the Safety and Tolerability of the 61 mg Tablet in Healthy Adults Under Fed Conditions
Source: EU CTIS (euclinicaltrials.eu) · Last updated 3 Apr 2026
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- First submitted
- 5 Feb 2026
- Start date
- 16 Mar 2026
- Lead sponsor
- Pfizer Inc.
- EU CT number
- 2026-525342-29-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 24
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pfizer Clinical Research Unit | Brussels | Belgium | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.